Definition & Case Presentation
| Question | Answer |
|---|---|
| 1. How is Neonatal Jaundice clinically defined? | The yellow discoloration of the skin, sclera, and mucous membranes caused by the accumulation of bilirubin in tissues, clinically detectable in newborns when total serum bilirubin (TSB) exceeds 5 mg/dL (85μmol/L). |
| 2. Why is jaundice clinically apparent at a lower threshold in adults compared to neonates? | In adults, jaundice is clinically detectable when serum bilirubin exceeds 2 to 3 mg/dL, whereas in neonates it is detectable only above 5 mg/dL due to neonates having higher skin vascularity, erythema, and subcutaneous fat characteristics. |
| 3. What percentage of term and preterm neonates develop clinical jaundice in the first week of life? | Approximately 60% of term neonates and 80% of preterm neonates develop clinical jaundice during the first week of life. |
| 4. What is the classic opening statement structure for a Neonatal Jaundice long case presentation? | A [Postnatal age in hours/days] old [Term/Preterm], [Male/Female] neonate, [AGA/SGA/LGA], born via [Mode of delivery] to a [Gravida/Parity] mother with [Mother's blood group] and baby's blood group [Group], presented with icterus noticed since [Day/Hour of life], currently [on phototherapy/asymptomatic/thriving], with [presence/absence] of high-risk features or encephalopathy. |
Physiological & Pathological Jaundice
| Question | Answer |
|---|---|
| 5. What are the 5 essential cardinal rules that define Physiological Jaundice in a term infant? | 1. Appears after 24 hours of life (typically day 2-3); 2. Peak TSB occurs on day 3-5 (≤ 12 to 15 mg/dL); 3. Rate of TSB rise is <5 mg/dL/24 hours (<0.2 mg/dL/hr); 4. Direct/conjugated bilirubin component is <1.0 mg/dL (or <20% of TSB); 5. Resolves spontaneously by 10-14 days without intervention. |
| 6. How does physiological jaundice differ in a Preterm neonate compared to a term neonate? | In preterm infants, physiological jaundice appears later (day 3-4), peaks later (day 5-7), reaches a higher peak level (12 to 15 mg/dL), and lasts longer (up to 2-3 weeks). |
| 7. What are the primary mechanisms responsible for physiological jaundice in a newborn? | 1. Increased bilirubin production (higher RBC mass per kg, shorter RBC lifespan of 80 days vs 120 days); 2. Immature hepatic uptake (low Y and Z ligandin proteins); 3. Impaired conjugation (deficient UDP-glucuronosyltransferase / UGT1A1 enzyme activity); 4. Enhanced enterohepatic circulation (lack of gut microflora, high intestinal β-glucuronidase). |
| 8. What criteria define Pathological Jaundice in a neonate? | 1. Appearance within the first 24 hours of life; 2. Rate of TSB rise >5 mg/dL/day or >0.2 mg/dL/hour; 3. TSB exceeding phototherapy/exchange transfusion thresholds on risk-specific charts; 4. Conjugated bilirubin >1.0 mg/dL (if TSB <5 mg/dL) or >20% of TSB; 5. Jaundice persisting >14 days in term or >21 days in preterm infants; 6. Presence of signs of systemic illness, clay-colored stools, or dark urine. |
Breastfeeding Jaundice
| Question | Answer |
|---|---|
| 9. What is the most common cause of jaundice appearing within the first 24 hours of life? | Hemolytic disease of the newborn (Rh isoimmunization, ABO incompatibility, minor group incompatibility, or red cell enzyme deficiencies like G6PD deficiency), or intra-uterine/perinatal infections (TORCH, early-onset sepsis). |
| 10. Differentiate Breastfeeding Jaundice from Breast Milk Jaundice. | Breastfeeding Jaundice (Lactation failure jaundice): Occurs in early 1st week due to inadequate milk intake, fluid deprivation, sluggish bowel motility, and increased enterohepatic circulation. Breast Milk Jaundice: Occurs in late 1st week to 2nd-4th week in a thriving, well-gaining infant due to inhibitors in breast milk (β-glucuronidase, non-esterified fatty acids, pregnane-3α,20β-diol) that enhance intestinal bilirubin absorption. |
| 11. VIVA TRAP: Should breastfeeding be discontinued in a baby with Breast Milk Jaundice? | NO. Breastfeeding should NOT be stopped. If TSB is below exchange thresholds, phototherapy is given if indicated while continuing exclusive breastfeeding. Stopping breastfeeding causes maternal anxiety and lactation disruption; temporary interruption (24-48 hrs) is reserved only for rare, extreme diagnostic uncertainty. |
Clinical Assessment — Kramer & TcB
| Question | Answer |
|---|---|
| 12. What is Kramer's Dermal Zones / Kramer's Rule for visual assessment of jaundice? | A clinical method to estimate jaundice extent (cephalocaudal progression): Zone 1: Head and neck (≈ 4–6 mg/dL); Zone 2: Upper trunk to navel (≈ 6–8 mg/dL); Zone 3: Lower trunk to knees (≈ 8–12 mg/dL); Zone 4: Arms and lower legs (≈ 12–14 mg/dL); Zone 5: Palms and soles (>15 mg/dL). |
| 13. VIVA TRAP: Can Kramer's rule be relied upon to make therapeutic decisions regarding phototherapy? | NO. Visual estimation under Kramer's rule is highly subjective, inaccurate in dark-skinned infants, underestimates jaundice under bright room lights, and is completely invalid once phototherapy has been initiated (as dermal blanching occurs unevenly). Serum or transcutaneous bilirubin measurement is mandatory. |
| 14. What is Transcutaneous Bilirubinometry (TcB), and how does it work? | A non-invasive optical device that measures multi-wavelength spectral reflectance from subcutaneous tissue (forearm, sternum) to estimate dermal bilirubin concentration. |
| 15. What are the clinical limitations of Transcutaneous Bilirubinometry (TcB)? | 1. Unreliable at TSB levels >15 mg/dL; 2. Unreliable after phototherapy initiation (skin is "bleached"); 3. Affected by skin pigmentation and local edema; 4. TcB reading within 3 mg/dL of the phototherapy threshold requires confirmation by Total Serum Bilirubin (TSB). |
Bilirubin Metabolism & Biochemistry
| Question | Answer |
|---|---|
| 16. Outline the biochemical pathway of Heme breakdown to Bilirubin. | Senescent RBCs/Heme →{Heme Oxygenase Biliverdin IXα + Carbon Monoxide (CO) + Iron →{Biliverdin Reductase Unconjugated Bilirubin (4Z,15Z-bilirubin). |
| 17. How is Carbon Monoxide (CO) production related to bilirubin production? | Equal equimolar amounts of CO and biliverdin are generated per molecule of heme broken down. End-Tidal Carbon Monoxide (ETCOc) measurement serves as a direct biomarker for the rate of active hemolysis in vivo. |
| 18. How is Unconjugated Bilirubin transported in blood to the liver? | It binds reversibly and non-covalently to Serum Albumin at a 1:1 primary high-affinity binding site. Only the unbound fraction ("Free Bilirubin") can cross the blood-brain barrier. |
| 19. What proteins mediate the intracellular hepatic uptake of bilirubin? | Ligandin (Organic Anion Binding Protein / Y protein, GST-A1) and Z protein within hepatocytes. |
| 20. Which enzyme converts Unconjugated Bilirubin into Conjugated Bilirubin? | Uridine Diphosphate-Glucuronosyltransferase 1A1 (UGT1A1) in the smooth endoplasmic reticulum, adding glucuronic acid molecules to form bilirubin monoglucuronide and diglucuronide. |
| 21. What enzyme in the neonatal gut deconjugates bilirubin back into unconjugated bilirubin? | β-Glucuronidase, present in high concentrations in fetal/neonatal intestinal mucosa and breast milk, converting conjugated bilirubin back to unconjugated bilirubin for reabsorption into the portal circulation (Enterohepatic Circulation). |
| 22. Why do neonates lack the ability to convert bilirubin to urobilinogen in the early days of life? | Neonates lack anaerobic gut microflora (Clostridium, Bacteroides) required to reduce bilirubin into urobilinogen and stercobilinogen; flora establishes gradually with enteral feeding. |
| 23. What is the total blood volume of a term neonate vs a preterm neonate? | Term neonate: ≈ 80 to 85 mL/kg; Preterm neonate: ≈ 90 to 100 mL/kg. |
| 24. What is the physiological lifespan of fetal RBCs compared to adult RBCs? | Fetal RBCs: 80 to 90 days; Adult RBCs: 120 days. |
| 25. What rate of bilirubin production occurs in a normal neonate vs an adult? | Neonates produce 8 to 10 mg/kg/day of bilirubin (more than double the adult rate of 3 to 4 mg/kg/day). |
| 26. What constitutes the "Direct" vs "Indirect" fraction in a laboratory LFT report? | Indirect Bilirubin = Unconjugated Bilirubin (water-insoluble, lipid-soluble); Direct Bilirubin = Conjugated Bilirubin (water-soluble, polar glucuronides). |
| 27. What level defines Conjugated Hyperbilirubinemia (Cholestasis)? | Direct Bilirubin >1.0 mg/dL (if Total Serum Bilirubin is <5.0 mg/dL) OR Direct Bilirubin >20% of Total Serum Bilirubin (if TSB is >5.0 mg/dL). |
Bilirubin Encephalopathy & Kernicterus
| Question | Answer |
|---|---|
| 28. VIVA TRAP: Can Conjugated Hyperbilirubinemia ever cause Kernicterus? | NO. Conjugated bilirubin is water-soluble, bound to glucuronide, highly polar, and cannot cross the intact blood-brain barrier. Kernicterus is caused exclusively by free unconjugated bilirubin. |
| 29. What is BIND (Bilirubin-Induced Neurological Dysfunction)? | A spectrum of neurological disorders caused by free unconjugated bilirubin toxicity across the central nervous system, ranging from subtle cognitive/auditory deficits (BIND) to Acute Bilirubin Encephalopathy (ABE) and Kernicterus Spectrum Disorders (KSD). |
| 30. What is Acute Bilirubin Encephalopathy (ABE)? | The acute clinical central nervous system manifestations of bilirubin toxicity in the neonatal period, categorized into Phase 1 (Mild/Early), Phase 2 (Moderate/Intermediate), and Phase 3 (Severe/Advanced). |
| 31. Describe the clinical features of Phase 1 (Early) Acute Bilirubin Encephalopathy. | Lethargy, poor sucking, hypotonia, stupor, decreased spontaneous movements, and loss of Moro reflex. (Reversible with prompt exchange transfusion/phototherapy). |
| 32. Describe the clinical features of Phase 2 (Intermediate) Acute Bilirubin Encephalopathy. | Moderate stupor, irritability, hypertonia, retrocollis (backward arching of neck), opisthotonos (backward arching of trunk), high-pitched cry, fever, and sun-setting sign. |
| 33. Describe the clinical features of Phase 3 (Advanced) Acute Bilirubin Encephalopathy. | Deep coma, persistent opisthotonos/retrocollis, seizures, apnea, pronounced extensor spasms, inability to feed, and cardiac arrest. (High mortality; survivors suffer permanent neurological damage). |
| 34. What is Kernicterus (Chronic Bilirubin Encephalopathy)? | The permanent, irreversible chronic neurological sequelae of severe hyperbilirubinemia characterized pathologically by yellow staining and neuronal necrosis in specific brain regions. |
| 35. Which specific brain structures are characteristically damaged in Kernicterus? | 1. Globus Pallidus (internal segment) and subthalamic nucleus; 2. Auditory brainstem nuclei (cochlear nuclei, inferior colliculus); 3. Oculomotor cranial nerve nuclei (CN III, IV, VI); 4. Hippocampus (CA2 region); 5. Cerebellar dentate nucleus. (Note: Cerebral cortex and thalamus are characteristically spared). |
| 36. What are the classical clinical quadriparesis features of established Kernicterus in older children? | 1. Choreoathetoid Cerebral Palsy (dystonia, choreoathetosis); 2. Sensorineural Hearing Loss or Auditory Neuropathy Spectrum Disorder (ANSD); 3. Oculomotor impairment (upward gaze palsy, sun-setting sign); 4. Dental enamel hypoplasia of primary teeth. |
| 37. Why are the Globus Pallidus and Auditory Brainstem Nuclei selectively vulnerable to bilirubin toxicity? | These regions have high metabolic rates, high membrane lipid turnover, dense capillary beds, and high oxygen consumption, making them sensitive to oxidative stress and excitotoxicity induced by free bilirubin. |
| 38. What imaging modality confirms chronic bilirubin encephalopathy, and what is the characteristic finding? | Brain MRI: Shows bilateral, symmetrical T1 hyperintensity in the Globus Pallidus and subthalamic nuclei in the acute/neonatal phase, shifting to T2 hyperintensity in the globus pallidus in infancy/later childhood. |
| 39. What is the BIND (Bilirubin-Induced Neurological Dysfunction) Clinical Score? | A clinical scoring tool (0 to 12) assessing three parameters (Mental Status, Muscle Tone, Crying) scored 0-4 each, used to stratify severity of encephalopathy and monitor progression. |
Hemolytic Disease — Rh & ABO
| Question | Answer |
|---|---|
| 40. What is Rh Isoimmunization (Rh Hemolytic Disease of the Newborn)? | Development of maternal anti-D IgG antibodies in an Rh-negative (D^-) mother exposed to Rh-positive (D^+) fetal RBCs during pregnancy or delivery, leading to transplacental placental transfer of IgG anti-D antibodies that destroy fetal D^+ RBCs. |
| 41. Why does Rh isoimmunization typically affect the second Rh-positive pregnancy rather than the first? | Primary maternal immune response during the 1st pregnancy produces IgM antibodies (cannot cross placenta). Memory B cells form; subsequent exposure during 2nd pregnancy triggers rapid secondary anamnestic response producing high-affinity IgG antibodies (cross placenta freely). |
| 42. What volume of fetomaternal hemorrhage is sufficient to induce maternal Rh sensitization? | As little as 0.1 mL of Rh-positive fetal blood entering Rh-negative maternal circulation can trigger sensitization. |
| 43. What is Hydrops Fetalis? | Severe fetal immune or non-immune anemia resulting in high-output cardiac failure, tissue hypoxia, severe capillary leak, and fluid accumulation in ≥ 2 fetal body compartments (ascites, pleural effusion, pericardial effusion, generalized skin edema/anasarca). |
| 44. What is the mechanism of hyperbilirubinemia in Rh hemolytic disease after birth? | In utero, fetal bilirubin is cleared transplacentally by maternal liver. At delivery, cord clamping severs placental clearance; massive ongoing IgG-mediated extravascular hemolysis by splenic macrophages rapidly generates huge unconjugated bilirubin loads that overwhelm immature neonatal liver. |
| 45. What physical findings on cord blood or neonate at birth suggest severe Rh Isoimmunization? | Cord blood pallor, hepato-splenomegaly (extramedullary hematopoiesis), severe icterus within 2-4 hours, petechiae/purpura, hydrops (ascites, anasarca), and signs of heart failure. |
| 46. What laboratory parameters from Cord Blood indicate severe Rh Hemolytic Disease requiring immediate action? | 1. Cord Hemoglobin <10 to 11 g/dL (severe anemia); 2. Cord Total Bilirubin >4.5 to 5.0 mg/dL; 3. Positive Direct Coombs Test (DCT / DAT); 4. High reticulocyte count (>10–15%). |
| 47. What is ABO Incompatibility? | Hemolytic disease occurring when an Group O mother carries a Group A or B fetus, caused by naturally occurring anti-A or anti-B IgG antibodies crossing the placenta. |
| 48. Why does ABO Incompatibility occur almost exclusively in Group O mothers? | Group A or B individuals produce predominantly IgM anti-B or anti-A antibodies (cannot cross placenta). Group O individuals produce naturally occurring IgG anti-A and anti-B antibodies (IgG1, IgG3) which readily cross the placenta. |
| 49. Why is ABO Hemolytic Disease usually much milder than Rh Hemolytic Disease? | 1. Anti-A/anti-B antibodies bind to non-RBC tissue antigens (vascular endothelium, epithelial cells) neutralizing antibodies; 2. Fetal A/B antigens are weakly expressed on fetal RBC membranes compared to adult cells; 3. Lower density of A/B sites per RBC. |
| 50. Can ABO Incompatibility affect the first-born child? | YES. Naturally occurring maternal IgG anti-A/anti-B antibodies are present prior to pregnancy (induced by dietary/environmental antigen exposure), so firstborns are frequently affected. |
| 51. What peripheral blood smear findings are pathognomonic for ABO Incompatibility vs Rh Incompatibility? | ABO Incompatibility: Prominent Spherocytes, polychromasia, and anisocytosis. Rh Incompatibility: Nucleated RBCs (normoblasts), marked polychromasia, with absence/minimal spherocytes. |
| 52. What is the Direct Coombs Test (DCT / Direct Antiglobulin Test / DAT)? | A test detecting maternal IgG antibodies or complement bound directly to the surface of neonatal RBC membranes. Uses antihuman globulin (Coombs reagent). |
| 53. What is the Indirect Coombs Test (ICT / Indirect Antiglobulin Test)? | A test detecting unbound circulating anti-RBC antibodies in maternal serum. |
| 54. VIVA TRAP: Why is DCT often weakly positive or negative in confirmed ABO incompatibility? | Fetal RBCs have low density and sparse expression of A and B antigenic sites, resulting in fewer IgG molecules bound per cell (below standard agglutination threshold of DCT), despite causing micro-spherocytic hemolysis. |
| 55. What minor blood group incompatibilities can cause severe neonatal hyperbilirubinemia? | Anti-c, anti-E, anti-C, anti-e (Rh system), Kell (anti-K), Duffy (anti-Fy^a), and Kidd (anti-Jk^a) antibodies. (Note: Anti-Kell suppresses erythropoiesis in addition to causing hemolysis). |
Non-Immune Hemolysis & Conjugation Defects
| Question | Answer |
|---|---|
| 56. What is Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency? | An X-linked recessive enzymopathy impairing NADPH generation via the hexose monophosphate shunt, leaving RBCs vulnerable to oxidative damage and hemolysis. |
| 57. What triggers acute hyperbilirubinemia in G6PD deficient neonates? | Exposure to oxidative agents (maternal ingestion or topical application of naphtha/mothballs, Henna, anti-malarials, sulfonamides, infection), or acute impairment of bilirubin conjugation without overt massive hemolysis. |
| 58. What peripheral blood smear findings suggest GPD deficiency? | Bite cells (degmacytes), Blister cells, polychromasia, and Heinz bodies (supravital methyl violet stain showing denatured hemoglobin precipitates). |
| 59. What is Hereditary Spherocytosis? | An autosomal dominant defect in RBC membrane skeletal proteins (Ankyrin, β-spectrin, Band 3, Protein 4.2) leading to membrane loss, reduced surface-area-to-volume ratio, spherical shape, osmotic fragility, and splenic sequestration. |
| 60. What diagnostic test confirms Hereditary Spherocytosis? | Osmotic Fragility Test (increased fragility), Incubated Osmotic Fragility, or Eosin-5-Maleimide (EMA) binding test on flow cytometry (gold standard). |
| 61. Differentiate Crigler-Najjar Syndrome Type 1, Crigler-Najjar Syndrome Type 2, and Gilbert Syndrome. | Crigler-Najjar Type 1: Autosomal recessive; Complete absence (0%) of UGT1A1 activity; severe hyperbilirubinemia (20–45 mg/dL); phenobarbital non-responsive; high kernicterus risk. Crigler-Najjar Type 2: Autosomal dominant/recessive; Severe reduction (<10%) of UGT1A1 activity; TSB 6–20 mg/dL; responds to phenobarbital (TSB drops >30%). Gilbert Syndrome: Common benign mutation (TA insertion in promoter region A(TA)7TAA); Moderate reduction (≈ 30%) of UGT1A1 activity; mild transient hyperbilirubinemia under stress. |
| 62. What simple test differentiates Crigler-Najjar Type 1 from Type 2? | Phenobarbital Response Test: Administer phenobarbital (5 mg/kg/day) for 7-10 days. In CN Type 2, serum bilirubin drops by >30%; in CN Type 1, there is zero reduction in bilirubin level. |
| 63. What is Lucey-Driscoll Syndrome (Transient Familial Neonatal Hyperbilirubinemia)? | A rare familial disorder where maternal serum contains a potent circulating inhibitor of UGT1A1 enzyme (a gestational steroid), causing severe transient unconjugated hyperbilirubinemia in all offspring during 1st 48 hours. |
| 64. What is the mechanism of hyperbilirubinemia in Extravasated Blood (Cephalhematoma / Subgaleal Hematoma / Bruising)? | Internal breakdown of RBCs trapped within closed tissue spaces releases large quantities of heme, overloading hepatic clearance and conjugating machinery. |
Other Unconjugated Causes
| Question | Answer |
|---|---|
| 65. Why does Polycythemia cause neonatal hyperbilirubinemia? | Venous hematocrit ≥ 65% increases total circulating RBC mass; destruction of excess RBCs generates proportionally higher daily bilirubin production. |
| 66. What is the Mechanism of Action of Phototherapy? | Absorption of blue-green light photons by unconjugated 4Z,15Z-bilirubin in dermal and subcutaneous capillaries induces 3 photochemical reactions converting it into water-soluble excretable isomers. |
Phototherapy
| Question | Answer |
|---|---|
| 67. What are the three photochemical reactions produced by Phototherapy? | 1. Structural Isomerization (Irreversible, main pathway): Converts 4Z,15Z-bilirubin into Lumirubin (cyclobilirubin), rapidly excreted in bile/urine without conjugation. 2. Configurational / Photo-isomerization (Reversible, rapid): Converts 4Z,15Z to 4Z,15E-bilirubin, excreted into bile but can revert back. 3. Photo-oxidation (Slow, minor): Converts bilirubin into small polar colorless pyrroles excreted in urine. |
| 68. What single photochemical product is most responsible for the efficacy of phototherapy? | Lumirubin (Structural Isomer). Its formation is irreversible, rate-dependent on light intensity/irradiance, and excreted independently of hepatic conjugation. |
| 69. What peak spectrum / wavelength of light is required for effective phototherapy? | Blue light in the narrow spectrum of 460 to 490 nm (matches peak absorption spectrum of bilirubin bound to albumin, which is 458 nm). |
| 70. What is the definition of Standard Phototherapy vs Intensive Phototherapy? | Standard Phototherapy: Irradiance of 8 to 10μW/cm^2/nm. Intensive Phototherapy: Spectral irradiance of ≥ 30μW/cm^2/nm delivered over as much body surface area as possible. |
| 71. How is Spectral Irradiance measured during phototherapy? | Using a calibrated Fluxmeter / Radiometer specifically matched to the waveband of the phototherapy unit. |
| 72. What factors determine the overall efficacy of phototherapy? | 1. Light wavelength (460-490 nm); 2. Spectral irradiance (≥ 30μW/cm^2/nm); 3. Exposed surface area of infant; 4. Distance between light source and baby (closer = higher irradiance, approx 30–45 cm); 5. Initial baseline serum bilirubin level. |
| 73. What types of lights are used in modern phototherapy units? | LEDs (Light Emitting Diodes) are preferred (blue spectral range, minimal heat output, long lifespan, high irradiance). Other types: Special blue fluorescent tubes (TL01), halogen lamps. |
| 74. Why are White LED or Blue LED units superior to conventional fluorescent tubes? | LEDs emit virtually no ultraviolet or infrared radiation, generate negligible heat, allow close positioning to the baby, last >20,000 hours, and deliver target irradiance ≥ 30μW/cm^2/nm. |
| 75. What essential protective equipment must be used on an infant during phototherapy? | 1. Opaque Eye Patches / Shields (prevents retinal damage and macular degeneration); 2. Genital / Diaper coverage (minimal size to maximize skin exposure while protecting gonads). |
| 76. What precautions must be observed regarding eye patch placement during phototherapy? | Ensure patches are securely fastened, do not slip down to occlude nostrils/airway, and remove patches periodically (during feeds) to inspect eyes for purulent discharge or conjunctivitis. |
| 77. How should fluid requirements be adjusted for a baby under conventional phototherapy? | Add 10 to 20% additional fluid volume (15–25 mL/kg/day) to compensate for increased Insensible Water Loss (IWL) and watery stool losses under non-LED phototherapy. (Note: Minimal extra fluid needed under modern cool LED units). |
| 78. Should phototherapy be interrupted during maternal breastfeeding feeds? | For non-critical TSB levels, phototherapy can be paused for 20–30 minutes for feeding and maternal bonding. If TSB is approaching exchange transfusion levels, phototherapy should be continuous (feed expressed milk under phototherapy). |
| 79. List 8 potential adverse effects / complications of Phototherapy. | 1. Insensible water loss & dehydration; 2. Temperature instability (hyperthermia/hypothermia); 3. Loose, frequent, green stools (biliary salt irritation); 4. Transient erythematous skin rash / maculopapular eruption; 5. Retinal damage (if unshielded); 6. Bronze Baby Syndrome (if cholestasis present); 7. Hypocalcemia; 8. DNA strand breaks / oxidative stress; 9. Maternal-infant separation / bonding disruption. |
| 80. What is Bronze Baby Syndrome? | A dark gray-brown discoloration of skin, serum, and urine occurring when phototherapy is administered to neonates with underlying conjugated hyperbilirubinemia (cholestasis), caused by photo-destruction and hepatic accumulation of copper-porphyrin complexes. |
| 81. Is Bronze Baby Syndrome an absolute contraindication to phototherapy if TSB is dangerously high? | NO. If unconjugated bilirubin is at critical risk levels for Kernicterus, phototherapy should be continued despite bronze discoloration, as unconjugated bilirubin poses the immediate neurotoxic risk. |
| 82. Why does Hypocalcemia occur as a side effect of phototherapy? | Phototherapy light suppresses pineal gland secretion of Melatonin, causing reduced inhibition of parathyroid hormone, driving calcium uptake into bones and secondary transient hypocalcemia. |
| 83. When can Phototherapy be safely discontinued? | When Total Serum Bilirubin falls 2 to 3 mg/dL below the initial phototherapy threshold line on the age/risk-specific nomogram (typically <12–13 mg/dL in term AGA infants). |
| 84. What is "Rebound Bilirubin", and when should it be routinely checked? | Rebound Bilirubin is an increase in TSB after phototherapy cessation due to ongoing hemolysis or tissue redistribution. Rebound testing (within 12-24 hours) is indicated in infants with hemolytic disease, DAT positive, gestation <37 weeks, or treatment initiated <72 hours of age. |
Exchange Transfusion & Adjunct Therapies
| Question | Answer |
|---|---|
| 85. What is an Exchange Transfusion (ET)? | An emergency life-saving procedure where the neonate’s blood is systematically removed and replaced in small aliquots with donor blood to rapidly clear free bilirubin, remove antibody-sensitized RBCs, and correct anemia. |
| 86. What are the primary therapeutic goals / indications for performing an Exchange Transfusion? | 1. Rapid clearance of circulating Unconjugated Bilirubin to prevent Kernicterus; 2. Removal of sensitized fetal RBCs and circulating maternal IgG antibodies; 3. Correction of severe anemia and restoration of oxygen-carrying capacity; 4. Removal of toxic metabolic products/cytokines. |
| 87. What are the clinical emergency indicators for performing Immediate Exchange Transfusion regardless of TSB level? | Presence of intermediate/advanced signs of Acute Bilirubin Encephalopathy (hypertonia, opisthotonos, retrocollis, fever, high-pitched cry, sun-setting sign), OR TSB level ≥ 5 mg/dL above exchange threshold on nomogram. |
| 88. Define Double Volume Exchange Transfusion (DVET). | An exchange transfusion using donor blood volume equal to twice the neonate's total blood volume (2 times 80–85 mL/kg = 160–170 mL/kg for term; 180–200 mL/kg for preterm). |
| 89. What percentage of circulating RBCs and serum bilirubin are removed by a Double Volume Exchange Transfusion? | Replaces approximately 85% of circulating neonate RBCs and lowers serum bilirubin levels by 50% (though rapid rebound occurs as tissue bilirubin equilibrates back into vascular space). |
| 90. What choice of Donor Blood is required for Rh Isoimmunization? | Group O, Rh-negative blood (or baby's ABO group, Rh-negative), cross-matched against maternal serum. |
| 91. What choice of Donor Blood is required for ABO Incompatibility? | Group O, Rh-compatible blood (Rh matches baby) with low-titer anti-A/anti-B antibody levels, or Group O RBCs reconstituted in Group AB plasma. |
| 92. What age and specification of donor blood must be used for neonatal Exchange Transfusion? | Fresh blood (<3–5 days old), irradiated (prevents Graft-versus-Host Disease), CMV negative, hematocrit adjusted to 45–50%, washed, and pre-warmed to 37^°C. |
| 93. Why must fresh blood (<5 days old) be used for exchange transfusion? | Older stored blood has high extracellular potassium (risk of lethal cardiac arrest/arrhythmias), low 2,3-DPG (poor tissue oxygen delivery), low pH (acidosis), and reduced platelet/clotting factor activity. |
| 94. What anticoagulant preservative is preferred in donor blood for exchange transfusion? | CPDA-1 (Citrate Phosphate Dextrose Adenine) or Citrate-Dextrose. |
| 95. What route/vessels are used to perform Exchange Transfusion? | 1. Isovolumetric / Double-line technique (Preferred): Continuous withdrawal via Umbilical Arterial Catheter (UAC) or peripheral artery, and simultaneous infusion via Umbilical Venous Catheter (UVC) or peripheral vein. 2. Single-line Push-Pull technique: Alternating withdrawal and infusion via UVC placed in Inferior Vena Cava. |
| 96. Describe the Push-Pull Technique cycle and aliquot sizes. | Aliquot size per pass: 5 mL/kg (10–15 mL for term infant; 5 mL for preterm). Each pull-push cycle takes 2-3 minutes; entire procedure takes 1.5 to 2 hours. |
| 97. VIVA TRAP: What is the correct catheter position for UVC during Exchange Transfusion? | The UVC tip should rest at the junction of the Inferior Vena Cava and Right Atrium (T8-T9 vertebral level, verified by X-ray). If used only for emergency push-pull, insertion depth is low (3–5 cm until free blood flow obtained, avoiding portal vein placement). |
| 98. Why is Calcium Gluconate administered during Exchange Transfusion, and what is the protocol? | Citrate in CPDA blood chelates free serum calcium, causing hypocalcemia. Administer 1 mL of 10% Calcium Gluconate IV slowly after every 100 mL of blood exchanged, under continuous cardiac rate monitoring. |
| 99. List 10 potential severe complications of Exchange Transfusion. | 1. Cardiac arrest / Arrhythmias (hyperkalemia, hypocalcemia); 2. Vascular thrombosis / Embolism / Portal vein thrombosis; 3. Necrotizing Enterocolitis (NEC); 4. Infection (sepsis, HBV, HIV, CMV); 5. Thrombocytopenia and coagulopathy; 6. Metabolic acidosis / alkalosis; 7. Hypoglycemia (rebound post-procedure); 8. Hypothermia; 9. Air embolism; 10. Perforation of umbilical vessels/bowel. |
| 100. Why must blood glucose be monitored closely after an Exchange Transfusion? | CPDA donor blood contains high dextrose concentration, stimulating fetal pancreatic insulin release. Once exchange finishes, high exogenous dextrose stops, leading to severe rebound hypoglycemia. |
| 101. What is the role of Intravenous Immunoglobulin (IVIG) in neonatal hemolytic jaundice? | IVIG blocks Fc receptors on reticuloendothelial macrophages in the spleen, preventing uptake and destruction of antibody-coated fetal RBCs, thereby blunting the rise of bilirubin and reducing the need for exchange transfusion. |
| 102. What is the AAP/IAP recommended dose and timing for IVIG administration? | Dose: 0.5 to 1.0 g/kg IV infused over 2 hours. Indicated in Rh or ABO hemolytic disease when TSB is rising despite intensive phototherapy or within 2 to 3 mg/dL of exchange threshold. Dose can be repeated in 12 hours if needed. |
| 103. What is the role of Metalloporphyrins (e.g., Stannic Porphimer / Tin Protoporphyrin) in jaundice management? | Competitive inhibitors of Heme Oxygenase, the rate-limiting enzyme converting heme to biliverdin, directly blocking bilirubin synthesis at its source. (Experimental/investigational use). |
| 104. What is the mechanism of action of Phenobarbital in jaundice treatment? | Induces hepatic UGT1A1 enzyme synthesis, increases cytosolic ligandin (Y protein) levels, and enhances bile flow (choleretic effect). Takes 3-7 days to act; used in Crigler-Najjar Type 2 and Gilbert syndrome (NOT for acute neonatal jaundice emergency). |
| 105. What is the role of Ursodeoxycholic Acid (UDCA) in neonatal jaundice? | Promotes choleresis, protects cholangiocytes from toxic bile salts, and stimulates biliary excretion; indicated exclusively in Conjugated Hyperbilirubinemia / Neonatal Cholestasis (10–20 mg/kg/day). |
Guidelines & Nomograms
| Question | Answer |
|---|---|
| 106. What is the Bhutani Nomogram? | A hour-specific percentile-based total serum bilirubin nomogram (for healthy neonates ≥ 35 weeks) stratified into Low Risk (<40^{th%ile), Low-Intermediate (40–75^{th%ile), High-Intermediate (75–95^{th%ile), and High Risk (>95^{th%ile) zones to predict risk of subsequent severe hyperbilirubinemia. |
| 107. According to AAP 2022 revised guidelines, what major structural change was made to phototherapy threshold charts? | Phototherapy thresholds were raised slightly across all gestational age groups based on new safety data showing low risk of kernicterus at higher TSB levels in the absence of hyperbilirubinemia neurotoxicity risk factors. |
| 108. List the key Neurotoxicity Risk Factors that lower the threshold for phototherapy/exchange transfusion on AAP/IAP charts. | 1. Gestational age <38 weeks; 2. Isoimmune hemolytic disease (Rh, ABO, minor group); 3. G6PD deficiency; 4. Severe asphyxia / Hypoxic-Ischemic Encephalopathy; 5. Significant lethargy; 6. Temperature instability; 7. Sepsis; 8. Serum albumin <3.0 g/dL. |
| 109. What ratio of Total Serum Bilirubin to Serum Albumin (TSB/Alb ratio) is used as an adjunct criteria for Exchange Transfusion? | TSB (mg/dL) / Albumin (g/dL) ratio: >8.0 (Risk Category 1: ≥ 38 wks without risk factors); >7.2 (Risk Category 2: ≥ 38 wks with risk factors OR 35–37 wks without); >6.8 (Risk Category 3: 35–37 wks with risk factors). |
Laboratory Evaluation
| Question | Answer |
|---|---|
| 110. What basic laboratory panel must be ordered when evaluating a neonate presenting with pathological jaundice? | 1. Total and Direct Serum Bilirubin; 2. Mother and Baby Blood Group (ABO and Rh); 3. Direct Coombs Test (DCT); 4. Complete Blood Count (CBC) with Reticulocyte count; 5. Peripheral Blood Smear (morphology, spherocytes, bite cells); 6. Serum Albumin. |
| 111. What reticulocyte percentage indicates active hemolysis in a neonate in the first 48 hours of life? | Reticulocyte count >5 to 7% in the first 48 hours of life (normal is 2–5%, falling to <2% by day 7). |
| 112. How do you calculate the Absolute Reticulocyte Count (ARC)? | ARC (/mm^3) = frac{Reticulocyte % times RBC Count (/mm^3){100. Normal ARC is <100,000/μL. |
| 113. What peripheral smear findings point toward specific causes of non-immune hemolytic anemia? | Spherocytes → Hereditary Spherocytosis / ABO incompatibility; Elliptocytes → Hereditary Elliptocytosis; Fragmentation / Schistocytes → Microangiopathic hemolysis / DIC / Sepsis; Heinz bodies / Bite cells → G6PD deficiency. |
| 114. How is a Micro-ESR interpreted in suspected septic jaundice? | Micro-ESR >15 mm in the 1st hour (or calculated as > Postnatal age in days + 3) is considered abnormal and supports sepsis. |
| 115. What is the significance of checking Serum Albumin in severe hyperbilirubinemia? | Albumin binds unconjugated bilirubin. Low serum albumin (<3.0 g/dL) reduces binding capacity, increasing circulating Free Bilirubin (Bf) and increasing neurotoxicity risk at lower TSB levels. |
| 116. What drugs displace bilirubin from its binding site on serum albumin and must be avoided in neonates? | Ceftriaxone, Sulfonamides (Co-trimoxazole), Salicylates, NSAIDs, Diazepam, Chloral hydrate, and Rapid Ampicillin infusion. |
| 117. Why is Ceftriaxone specifically contraindicated in neonates with jaundice? | Ceftriaxone displaces bilirubin from albumin binding sites, increasing free toxic bilirubin; it also forms insoluble calcium-ceftriaxone precipitates in biliary tract and lungs. (Cefotaxime is used instead). |
Prolonged Jaundice & Cholestasis Overview
| Question | Answer |
|---|---|
| 118. What defines Prolonged Neonatal Jaundice? | Jaundice that persists beyond 14 days of life in term infants and beyond 21 days of life in preterm infants. |
| 119. What are the primary differential diagnoses for Prolonged Unconjugated Hyperbilirubinemia? | 1. Breast Milk Jaundice (most common); 2. Congenital Hypothyroidism; 3. Ongoing Hemolysis (G6PD deficiency, spherocytosis); 4. Crigler-Najjar Syndrome (Type 1 or 2); 5. Extravasated blood resolution (cephalhematoma); 6. Pyloric Stenosis / Intestinal Obstruction. |
| 120. What are the primary differential diagnoses for Prolonged Conjugated Hyperbilirubinemia (Neonatal Cholestasis)? | 1. Biliary Atresia (most urgent); 2. Idiopathic Neonatal Hepatitis; 3. Choledochal Cysts; 4. Progressive Familial Intrahepatic Cholestasis (PFIC); 5. Alagille Syndrome; 6. Metabolic disorders (α1-antitrypsin deficiency, Galactosemia, Tyrosinemia); 7. TORCH / Systemic infections. |
| 121. What physical stool appearance confirms Neonatal Cholestasis? | Pale, clay-colored, or acholic stools (lack of stercobilin entry into intestine due to biliary obstruction). |
| 122. What physical urine appearance suggests Conjugated Hyperbilirubinemia? | Dark, tea-colored urine that stains the diaper yellow. (Unconjugated bilirubin is water-insoluble and does NOT pass into urine; conjugated bilirubin is water-soluble and excreted in urine). |
| 123. Why is early diagnosis of Biliary Atresia critical? | Kasai Portoenterostomy surgery must be performed ideally within the first 60 days of life (<8 weeks) to achieve native liver survival and prevent irreversible biliary cirrhosis. |
| 124. What key investigation differentiates Biliary Atresia from Neonatal Hepatitis? | Hepatobiliary Scintigraphy (HIDA / PIPIDA Scan): Shows good hepatic uptake but complete absence of tracer excretion into the intestine at 24 hours in Biliary Atresia (after 5 days of phenobarbital priming). |
| 125. What radiological USG sign is pathognomonic for Biliary Atresia? | The Triangular Cord Sign (a triangular hyperechoic fibrous mass >4 mm located anterior to the portal vein bifurcation). |
| 126. What is the Kasai Procedure (Hepatoportoenterostomy)? | Surgical resection of the extrahepatic fibrous biliary remnant at the porta hepatis and creation of a Roux-en-Y jejunal loop anastomosed to the porta hepatis to restore bile drainage. |
| 127. How does Congenital Hypothyroidism cause unconjugated hyperbilirubinemia? | Thyroid hormone deficiency delays maturation of hepatic ligandin (Y protein) and UGT1A1 enzyme activity, slowing conjugation and biliary excretion. |
| 128. How does Hyperbilirubinemia present in infants with Galactosemia? | Presents after initiation of milk feeds (end of 1st week) with conjugated/mixed jaundice, hepatomegaly, cataracts, lethargy, poor feeding, vomiting, hypoglycemia, and E. coli sepsis. |
| 129. What simple bed-side urine screening test points to Galactosemia? | Urine non-glucose reducing substances positive (Clinitest positive) while urine glucose dipstick is negative. |
| 130. How does Infantile Hypertrophic Pyloric Stenosis cause jaundice? | Increased enterohepatic circulation secondary to gastric outlet obstruction, combined with starvation-induced downregulation of hepatic UGT1A1 expression. |
Physical Signs in Jaundice
| Question | Answer |
|---|---|
| 131. Describe the pathognomonic physical finding in Rh Hemolytic Hydrops. | Severe pale anasarca, gross ascites, pleural/pericardial effusions, hepatosplenomegaly, and purpuric skin lesions ("blueberry muffin" spots from extramedullary hematopoiesis). |
| 132. What is the Sun-setting Sign (setting-sun eye phenomenon)? | Downward deviation of the eyes with sclera visible above the iris, caused by compression/toxicity of the midbrain tectum and oculomotor nerve pathways. Sign of advanced ABE or raised ICP. |
| 133. What is the Riga-Fede Disease? | Ventral tongue ulceration caused by traumatic abrasion against natal/neonatal teeth during sucking. |
| 134. What is the Triangular Cord Sign on liver ultrasound? | A cone-shaped hyperechoic fibrous ductal plate thickness >4 mm cranial to the portal vein bifurcation, pathognomonic for Biliary Atresia. |
| 135. What physical sign differentiates a Cephalhematoma from Subgaleal Hemorrhage? | Cephalhematoma is strictly limited by suture lines. Subgaleal hemorrhage crosses suture lines, is fluctuant, expands rapidly, and shifts dependent fluid with gravity. |
VIVA TRAPs — Clinical Pitfalls
| Question | Answer |
|---|---|
| 136. VIVA TRAP: "If an infant has severe jaundice and dark tea-colored urine that stains the diaper, what type of hyperbilirubinemia is present?" | Conjugated (Direct) Hyperbilirubinemia. Unconjugated bilirubin is lipid-soluble, bound to albumin, non-polar, and cannot be filtered by glomeruli. Only conjugated bilirubin is water-soluble and excreted in urine. |
| 137. VIVA TRAP: "A 36-hour-old baby has TSB 14 mg/dL. Mother is O Positive and baby is A Positive. DCT is negative. Can you rule out ABO Incompatibility?" | NO. DCT is negative or weakly positive in up to 50% of clinical ABO incompatibilities. Spherocytes on peripheral smear, reticulocytosis, and ABO setup confirm the diagnosis. |
| 138. VIVA TRAP: "Is sunlight exposure recommended as a safe treatment for neonatal jaundice?" | NO. AAP and IAP strictly advise against exposing infants to direct sunlight due to risk of sunburn, dehydration, hypothermia/hyperthermia, ultraviolet skin damage, and uncalibrated irradiance. |
| 139. VIVA TRAP: "Mother says her baby's skin looks less yellow after 24 hours of phototherapy, but TSB is unchanged. Why?" | Phototherapy bleaches bilirubin in the superficial dermis via photo-isomerization, giving a false impression of clearing skin color while systemic intravascular bilirubin remains high. (This is why TcB is invalid during phototherapy). |
| 140. VIVA TRAP: "Should you give prophylactic IV Calcium Gluconate routinely to every baby undergoing exchange transfusion?" | YES. CPDA blood contains citrate which chelates calcium. 1 mL of 10% Calcium Gluconate is administered slowly after every 100 mL of blood exchanged under continuous heart rate monitoring. |
| 141. VIVA TRAP: "If a baby under phototherapy develops green, loose stools, should phototherapy be stopped?" | NO. Green loose stools are a expected benign side effect caused by accelerated excretion of photo-isomers and unabsorbed bile salts in gut lumen. Continue phototherapy; maintain hydration. |
| 142. VIVA TRAP: "Does an infant with Kernicterus present with flaccid hypotonia or hypertonia in the acute phase?" | Phase 1 ABE presents with lethargy and hypotonia. Phase 2 ABE progresses to severe hypertonia, retrocollis, and opisthotonos. |
| 143. VIVA TRAP: "Can an Rh-negative mother carry her 1st Rh-positive child without sensitization if she receives Anti-D Immunoglobulin?" | An un-sensitized Rh-negative mother receives 300μg of Anti-D Ig at 28 weeks gestation and within 72 hours post-delivery of an Rh-positive baby to prevent primary sensitization. |
| 144. VIVA TRAP: "If direct bilirubin is 1.2 mg/dL and TSB is 18 mg/dL, is this Cholestasis?" | NO. Direct bilirubin is 1.2 mg/dL, which is <20% of TSB (1.2/18 = 6.6%). For TSB >5.0 mg/dL, cholestasis is defined as direct component >20% of TSB. |
| 145. VIVA TRAP: "A baby born at 38 weeks has TSB 16 mg/dL at 48 hours. Is this physiological jaundice?" | NO. TSB of 16 mg/dL exceeds the physiological limit (12–15 mg/dL) and reaches the phototherapy threshold for a 38-week infant at 48 hours. |
Rh Prophylaxis & Intrauterine Management
| Question | Answer |
|---|---|
| 146. What is the mechanism of action of Rho(D) Immune Globulin (Anti-D Ig / Rhogam)? | Exogenous anti-D IgG antibodies bind to and clear Rh-positive fetal RBCs from maternal circulation before maternal B lymphocytes can recognize D antigens and mount a primary immune response. |
| 147. What standard dose of Anti-D Immunoglobulin is given to an Rh-negative mother post-partum? | 300μg (1500 IU) IM administered within 72 hours of delivery of an Rh-positive fetus. |
| 148. How much fetal whole blood is neutralized by a standard 300μg dose of Anti-D Ig? | 300μg of Anti-D neutralizes up to 30 mL of fetal whole blood (or 15 mL of packed RBCs). |
| 149. What test is performed on maternal blood to detect massive fetomaternal hemorrhage exceeding 30 mL? | Kleihauer-Betke (KB) Test (acid elution test) or Flow Cytometry for fetal hemoglobin (HbF). |
| 150. Describe the principle of the Kleihauer-Betke (KB) Test. | Fetal hemoglobin (HbF) is resistant to acid elution, whereas adult hemoglobin (HbA) is eluted out. On acid-treated blood smears, fetal RBCs remain bright pink while adult RBCs appear as ghost cells. |
| 151. How is additional Anti-D dose calculated based on Kleihauer-Betke test results? | Fetal blood volume (mL) = frac{% Fetal cells times Maternal blood volume (5000 mL){100. Additional Anti-D doses (300μg per 30 mL fetal blood) are administered accordingly. |
| 152. What non-invasive antenatal ultrasound Doppler parameter predicts fetal anemia in Rh sensitized mothers? | Middle Cerebral Artery Peak Systolic Velocity (MCA-PSV). |
| 153. What MCA-PSV value indicates severe fetal anemia requiring intrauterine blood transfusion? | MCA-PSV >1.50 Multiples of the Median (MoM) for gestational age. |
| 154. Why does Peak Systolic Velocity in the fetal Middle Cerebral Artery increase in fetal anemia? | Fetal anemia reduces blood viscosity and increases cardiac output; hyperdynamic circulation increases arterial velocity. |
| 155. What is an Intrauterine Transfusion (IUT)? | Transfusion of Group O, Rh-negative, washed, irradiated, CMV-negative packed RBCs into the fetal umbilical vein under ultrasound guidance to correct severe fetal anemia and prevent hydrops. |
| 156. What is the target Hematocrit for fetal blood during an Intrauterine Transfusion? | Target fetal hematocrit post-transfusion is 45 to 50%. |
| 157. What are the indications for Antenatal Anti-D prophylaxis during an unsensitized Rh-negative pregnancy? | Administered routinely at 28 weeks gestation, and following any potential fetomaternal hemorrhage event (abortion, ectopic pregnancy, amniocentesis, CVS, blunt abdominal trauma, antepartum hemorrhage). |
| 158. Can Anti-D Immunoglobulin be administered if the mother is already sensitized (ICT positive)? | NO. Anti-D Ig is completely ineffective once maternal primary sensitization has occurred (positive ICT titer ≥ 1:16). |
| 159. What maternal ICT antibody titer threshold defines a "critical titer" requiring close fetal surveillance? | An Anti-D ICT titer of ≥ 1:16 (or 1:32 depending on laboratory). |
| 160. What is the Rosette Test? | A qualitative screening test for fetomaternal hemorrhage that detects small numbers of Rh-positive fetal RBCs in Rh-negative maternal blood using indicator Rh-positive cells that form rosettes around sensitized fetal cells. |
| 161. What is the incidence of ABO Incompatibility in all pregnancies? | ABO setup occurs in ≈ 15–20% of pregnancies, but clinical hemolytic disease develops in only ≈ 2–5% of offspring. |
| 162. Why is hydrops fetalis extremely rare in ABO Incompatibility? | Extravascular destruction is mild due to low antigenic site density and tissue binding of antibodies, preventing the severe intravascular anemia required to cause heart failure in utero. |
| 163. What is the primary pathway of bilirubin clearance in the fetus in utero? | Placental transfer of unconjugated bilirubin across fetal-maternal capillary membranes into maternal circulation for hepatic conjugation and excretion by maternal liver. |
| 164. Why does fetal liver conjugate very little bilirubin in utero? | Fetal UGT1A1 activity is <1% of adult levels until 30 weeks gestation, reaching only 0.1–1% at birth. Low conjugation keeps bilirubin unconjugated, enabling lipid-soluble clearance across the placenta. |
| 165. What is the role of Alpha-Fetoprotein (AFP) in neonatal jaundice evaluation? | Elevated in neonatal hepatitis; low or absent in some developmental liver anomalies. |
Cholestasis — Diagnosis & Hepatology
| Question | Answer |
|---|---|
| 166. What is the characteristic histology of Idiopathic Neonatal Hepatitis? | Panlobular giant cell transformation of hepatocytes, ballooning degeneration, extramedullary hematopoiesis, and lobular inflammation with patent extrahepatic bile ducts. |
| 167. What metabolic disorder presents with cholestatic jaundice, liver failure, and a characteristic cabbage-like or boiled-cabbage odor? | Hereditary Tyrosinemia Type 1 (Fumarylacetoacetate hydrolase deficiency). |
| 168. What diagnostic compound is elevated in urine in Tyrosinemia Type 1? | Succinylacetone. |
| 169. What metabolic defect causes α1-Antitrypsin Deficiency and cholestasis? | Homozygous PiZZ mutation causing misfolding and accumulation of insoluble α1-antitrypsin mutant protein polymers in the endoplasmic reticulum of hepatocytes. |
| 170. What histological liver biopsy finding is pathognomonic for α1-Antitrypsin Deficiency? | Periodic Acid-Schiff (PAS)-positive, diastase-resistant eosinophilic globules within periportal hepatocytes. |
| 171. What is Alagille Syndrome (Arteriohepatic Dysplasia)? | An autosomal dominant disorder (JAG1 or NOTCH2 mutation) characterized by paucity of interlobular bile ducts, characteristic facies (broad forehead, deep-set eyes, pointed chin), butterfly vertebrae, pulmonary artery stenosis, and posterior embryotoxon. |
| 172. What ocular sign is characteristic of Alagille Syndrome? | Posterior Embryotoxon (prominent, anteriorly displaced Schwalbe line on slit-lamp exam). |
| 173. Differentiate Progressive Familial Intrahepatic Cholestasis (PFIC) Type 1, 2, and 3 based on Serum Gamma-Glutamyl Transferase (GGT). | PFIC Type 1 (FIC1 defect) and PFIC Type 2 (BSEP defect): NORMAL or Low GGT with severe cholestasis. PFIC Type 3 (MDR3 defect): HIGH GGT cholestasis. |
| 174. What is a Choledochal Cyst? | Congenital cystic dilation of the extrahepatic or intrahepatic biliary tree (Classified I to V under Todani classification). Type I (fusiform extrahepatic dilation) is most common. |
| 175. What clinical triad characterizes Choledochal Cysts? | Jaundice, Right Upper Quadrant Abdominal Mass, and Abdominal Pain. (Triad present in <20% of neonates). |
| 176. What is the surgical treatment for a Type I Choledochal Cyst? | Complete cyst excision with Roux-en-Y Hepaticojejunostomy. |
| 177. What is Byler Disease? | Historical name for Progressive Familial Intrahepatic Cholestasis Type 1 (PFIC-1), characterized by low GGT cholestasis, severe pruritus, watery diarrhea, and progression to end-stage liver disease. |
| 178. Why does parenteral nutrition (TPN) cause cholestasis in infants? | Prolonged TPN (>2 weeks) lacks enteral stimulation (reducing CCK and bile flow), contains phytosterols in lipid emulsions, and leads to mucosal atrophy, toxic bile acid accumulation, and sepsis. |
| 179. What lipid formulation reduces TPN-associated cholestasis (PNAC/IFALD)? | Replacing soy-based lipid emulsions with Fish-oil-based lipid emulsions (Omegaven) rich in ω-3 fatty acids. |
| 180. What is Inspissated Bile Syndrome? | Transient extrahepatic or intrahepatic biliary sludge/plugging secondary to massive hemolysis (Rh disease) or prolonged fasting, causing temporary cholestasis that resolves spontaneously or with UDCA. |
Chronic Kernicterus Sequelae
| Question | Answer |
|---|---|
| 181. What is the role of Phenobarbital prior to a HIDA scan? | Administered at 5 mg/kg/day for 5 days prior to scan to induce hepatic clearance machinery and minimize false-positive non-excretion in neonatal hepatitis. |
| 182. What percentage of total serum bilirubin is typically bound to albumin? | Over 99.9% of circulating unconjugated bilirubin is bound to serum albumin; <0.1% exists as unbound "Free Bilirubin." |
| 183. What is the binding capacity of 1 gram of human albumin for bilirubin? | 1 gram of albumin binds approximately 8.5 mg of bilirubin at its primary high-affinity site. |
| 184. At what TSB level does the primary albumin binding site become saturated in a term neonate with normal albumin (3.5 g/dL)? | Saturated at TSB ≈ 25 to 30 mg/dL, beyond which Free Bilirubin levels rise exponentially. |
| 185. What physiological conditions impair albumin-bilirubin binding affinity and increase free bilirubin? | Acidosis (pH < 7.20), hypothermia, asphyxia, sepsis, hyperosmolality, and elevated free fatty acids. |
| 186. Why does Acidosis increase the neurotoxicity of bilirubin? | 1. Acidosis decreases albumin-bilirubin binding affinity; 2. Protonation of bilirubin anion forms lipid-soluble bilirubin acid (H2B), which readily precipitates into neural cell membranes. |
| 187. What is the function of the Blood-Brain Barrier (BBB) regarding bilirubin? | Tight junctions between cerebral endothelial cells and P-glycoprotein efflux pumps prevent albumin-bound bilirubin and restrict free bilirubin entry into the CNS. |
| 188. What clinical factors cause Blood-Brain Barrier disruption in a neonate? | Hyperosmolality (rapid sodium/mannitol shifts), severe hypoxia, hypercapnia (PaCO2 > 60 mmHg), intraventricular hemorrhage, and sepsis/meningitis. |
| 189. Describe the cellular mechanism of Bilirubin-induced neuronal cell death. | Free bilirubin enters neurons → inhibits mitochondrial cytochrome oxidase → impairs ATP synthesis → causes cell membrane lipid peroxidation → induces intracellular calcium influx → triggers apoptotic and necrotic cell death cascades. |
| 190. What auditory test is most sensitive for detecting early Bilirubin Neurotoxicity? | Auditory Brainstem Response (ABR / BERA): Shows prolongation of wave I-V interpeak latencies, loss or morphology alteration of wave V, or complete absence of responses (Auditory Neuropathy Spectrum Disorder). |
| 191. Why is Otoacoustic Emission (OAE) normal in infants with Bilirubin Auditory Neuropathy? | OAE tests outer hair cell function in the organ of Corti (which is undamaged). Bilirubin damages the cochlear nerve and auditory brainstem nuclei, causing abnormal AABR despite normal OAE. |
| 192. What is Auditory Neuropathy Spectrum Disorder (ANSD)? | A hearing disorder characterized by normal outer hair cell function (Normal OAE) but absent or severely disordered neural conduction along auditory brainstem pathways (Abnormal ABR). |
| 193. Is Bilirubin-induced Auditory Neuropathy reversible? | Mild ABR changes (Wave V latency prolongation) can reverse if prompt exchange transfusion or intensive phototherapy lowers bilirubin levels immediately. |
| 194. What is the characteristic dental anomaly seen in children with prior severe neonatal hyperbilirubinemia? | Enamel Hypoplasia and Greenish/Yellow discoloration (Chlorodontia) of primary deciduous teeth. |
| 195. Why do primary teeth turn green in Kernicterus survivors? | Bilirubin deposits directly into developing dentin and enamel matrices during the active calcification phase of fetal/neonatal tooth buds. |
| 196. What motor deficit dominates in established Kernicterus? | Choreoathetoid Dyskinetic Cerebral Palsy (dystonia, chorea, athetosis with preserved intellect in many cases). |
| 197. What ocular tracking deficit is characteristic of Kernicterus? | Upward gaze palsy (inability to look upward) due to damage to oculomotor pretectal nuclei. |
| 198. Describe the Sun-setting Sign. | Iris appears setting below the lower eyelid like a setting sun, exposing white sclera above, caused by midbrain/pretectal toxicity or hydrocephalus. |
| 199. What is the mortality rate of Phase 3 Advanced Acute Bilirubin Encephalopathy? | Approximately 50 to 75%; survivors universally develop severe chronic Kernicterus. |
Phototherapy — Practical Management
| Question | Answer |
|---|---|
| 200. What is the total surface area exposure percentage achieved by Single Surface vs Double Surface phototherapy? | Single surface: Exposes ≈ 35% of body surface area. Double surface (above and below): Exposes ≈ 80% of body surface area. |
| 201. What simple modification increases light intensity during phototherapy? | Lining the sides of the bassinet/cot with white reflective curtains or aluminum foil increases effective irradiance by 20 to 30%. |
| 202. What is the recommended distance between a fluorescent phototherapy lamp and the infant? | Approximately 30 to 45 cm. (Fluorescent lamps cannot be placed closer due to thermal burn risk). |
| 203. How close can a Blue LED phototherapy unit be safely positioned relative to the infant? | Can be placed within 10 to 15 cm of the baby (since LEDs generate negligible heat), drastically increasing spectral irradiance. |
| 204. Why must a baby's position be turned periodically (every 2-3 hours) during phototherapy? | Position changes (supine to prone) expose fresh skin areas to photon absorption, accelerating structural photo-isomerization. |
| 205. How often should Total Serum Bilirubin be re-assessed after starting Intensive Phototherapy for severe hyperbilirubinemia? | Re-check TSB within 4 to 6 hours of initiating intensive phototherapy. |
| 206. What rate of drop in TSB is expected under Intensive Phototherapy during the first 4-8 hours? | TSB should drop by 1.0 to 2.0 mg/dL per hour (or 30–40% total drop in first 24 hours) in non-hemolytic hyperbilirubinemia. |
| 207. What failure rate of TSB drop under intensive phototherapy indicates ongoing severe hemolysis or need for exchange transfusion? | Failure of TSB to drop, or a continued rise of >0.2 mg/dL/hour despite intensive phototherapy. |
| 208. Should a baby under phototherapy be given routine supplemental IV fluid or oral water/dextrose? | NO. Routine IV fluid or oral dextrose water is NOT recommended in well-hydrated, enterally fed infants. Enteral breast milk promotes bowel motility and stooling, clearing bilirubin faster than IV fluids. |
| 209. When IS fluid supplementation indicated during phototherapy? | Indicated ONLY if there is clinical evidence of dehydration, hypernatremia, weight loss >10%, or TSB approaching exchange transfusion level. |
| 210. What type of fluid is used for IV rehydration in hyperbilirubinemic dehydration? | Isotonic fluids (10–20 mL/kg Normal Saline bolus if shocked, followed by 1/5^{th NS in 10% Dextrose based on serum sodium). |
| 211. Why are Biliblankets / Fiberoptic Phototherapy pads used primarily as adjuncts rather than primary therapy in term infants? | Fiberoptic pads cover a small surface area and deliver lower irradiance; used mainly as adjuncts to overhead light or for home phototherapy in low-risk infants. |
| 212. What light wavelength is harmful and must be filtered out by phototherapy glass filters? | Ultraviolet light (<400 nm) and Infrared light (>700 nm). |
| 213. What is the risk of using phototherapy in an infant with Congenital Erythropoietic Porphyria? | Causes severe, blistering bullous lesions, skin necrosis, and life-threatening photo-mutilation. (Absolute contraindication). |
| 214. How does phototherapy affect serum gonadotropin levels if genitals are unshielded? | Phototherapy light exposure to bare testes can cause cellular damage, testicular heat damage, and alter germ cell maturation. |
| 215. Why is Temperature monitoring mandatory every 3-4 hours during phototherapy? | Overheating from lamps causes hyperthermia; naked exposure causes hypothermia if room air is cold. |
Exchange Transfusion — Procedure & Complications
| Question | Answer |
|---|---|
| 216. What is the formula to calculate the blood volume required for a Double Volume Exchange Transfusion? | Donor Blood Volume (mL) = 2 times Blood Volume (mL/kg) times Body Weight (kg). (≈ 160 mL/kg for term; 180 mL/kg for preterm). |
| 217. How do you calculate the expected post-exchange hematocrit? | Target post-exchange hematocrit is 45 to 50%. |
| 218. What temperature must donor blood be warmed to before Exchange Transfusion, and why? | Warmed to 37^°C using an inline blood warmer. Cold blood causes severe neonatal hypothermia, cardiac arrest, bradycardia, and vasospasm. |
| 219. VIVA TRAP: Should blood be warmed in a microwave or hot water bath? | NEVER. Microwaving or unmonitored hot water baths cause severe hemolysis of donor RBCs, leading to fatal hyperkalemic cardiac arrest upon infusion. |
| 220. What is the maximum duration an Exchange Transfusion procedure should take? | Should be completed within 1.5 to 2.0 hours. Procedures lasting >2 hours increase risk of infection, hypothermia, and hemodynamic instability. |
| 221. How often should vital signs (HR, RR, BP, SpO2, temperature) be recorded during Exchange Transfusion? | Every 15 minutes throughout the procedure and every 30 minutes for 4 hours post-procedure. |
| 222. What laboratory tests must be sent immediately prior to starting Exchange Transfusion? | Baseline TSB, Direct Bilirubin, CBC, Reticulocyte count, Blood Glucose, Electrolytes (Na^+, K^+, Ca^{2+), Blood Gas, and Blood Culture. |
| 223. What laboratory tests must be sent immediately after completing Exchange Transfusion? | Post-exchange TSB, CBC, Platelet count, Blood Glucose, Electrolytes (Na^+, K^+, Ca^{2+), and Blood Gas. |
| 224. What antibiotic prophylaxis is given after an Exchange Transfusion? | Broad-spectrum IV antibiotics (e.g., Ampicillin + Gentamicin) are maintained for 24-48 hours if catheter sterile technique was compromised or procedure was prolonged. |
| 225. Why does Thrombocytopenia commonly develop post-exchange transfusion? | Donor blood (CPDA stored) lacks functional platelets; exchange washes out recipient platelets. |
| 226. How is post-exchange rebound hyperbilirubinemia managed? | Resume continuous intensive phototherapy immediately after exchange transfusion; monitor TSB at 4-6 hours. |
| 227. What is the mechanism of Necrotizing Enterocolitis (NEC) following Exchange Transfusion? | Hemodynamic fluctuations in mesenteric blood flow during UVC push-pull cycles cause intestinal mucosal ischemia, reperfusion injury, and bacterial translocation. |
| 228. How long should enteral feeds be held after an Exchange Transfusion? | NPO (Nil Per Os) for at least 6 to 12 hours post-procedure to observe for intestinal ischemia/NEC. |
| 229. What is the mortality risk associated with neonatal Exchange Transfusion in modern NICUs? | Procedure-related mortality is 0.5 to 2.0% in healthy infants, but up to 10 to 12% in sick/preterm infants. |
| 230. How does Albumin Infusion (1 g/kg 20% Albumin) work prior to Exchange Transfusion? | Administered 1 hour prior to exchange to bind tissue-bound bilirubin, draw it into the vascular space, and maximize bilirubin removal during the exchange. |
| 231. What is the contraindication to Albumin Infusion prior to Exchange Transfusion? | Contraindicated in infants with elevated central venous pressure, heart failure, or severe anasarca/hydrops due to risk of fluid overload and pulmonary edema. |
| 232. What is the mechanism of Hypoglycemia during CPDA blood exchange transfusion? | CPDA contains glucose (300–400 mg/dL). Infusion stimulates endogenous insulin secretion; post-procedure drop in glucose intake causes rebound hyperinsulinemic hypoglycemia. |
| 233. What rate of IV Dextrose infusion should be maintained post-exchange transfusion? | Infuse 10% Dextrose at 6 to 8 mg/kg/min (GIR) and monitor blood glucose hourly for 4 hours. |
| 234. What is the risk of using Heparinized fresh whole blood for exchange transfusion? | Risk of severe rebound systemic bleeding/hemorrhage and severe hypocalcemia. (If used, Protamine Sulfate is required). |
Hemolytic Anemia Diagnostics
| Question | Answer |
|---|---|
| 235. What specific parameter on a peripheral blood smear differentiates Hereditary Spherocytosis from ABO Incompatibility? | Both show spherocytes; however, ABO incompatibility has a positive DCT (or mother O, baby A/B) and reticulocytosis, whereas Hereditary Spherocytosis has a negative DCT, family history, and elevated MCHC (>36 g/dL). |
| 236. What is the Mean Corpuscular Hemoglobin Concentration (MCHC) cutoff suggestive of Hereditary Spherocytosis? | MCHC >35.5 to 36.0 g/dL (due to cellular dehydration and membrane loss). |
| 237. Why is G6PD screening assay (fluorescent spot test / quantitative enzyme assay) often false normal during an acute hemolytic crisis? | During acute hemolysis, old G6PD-deficient RBCs are destroyed. The circulating blood consists predominantly of young reticulocytes which have normal/elevated enzyme levels, masking the deficiency. |
| 238. When should G6PD enzyme level testing be repeated if initially normal during a hemolytic crisis? | Repeat quantitative enzyme testing 2 to 3 months post-crisis when reticulocyte count normalizes and steady-state RBC population returns. |
| 239. What is Pyruvate Kinase (PK) Deficiency? | An autosomal recessive glycolytic enzymopathy causing impaired ATP production, rigid RBCs, chronic non-spherocytic hemolytic anemia, and severe neonatal hyperbilirubinemia. |
| 240. How is Pyruvate Kinase Deficiency diagnosed? | Direct assay of RBC Pyruvate Kinase enzyme activity. |
| 241. What minor blood group antibody is infamous for causing severe delayed hemolytic disease of the fetus and newborn via erythroid suppression as well as hemolysis? | Anti-Kell (anti-K) antibodies. Anti-K destroys Kell-expressing erythroid progenitor cells in bone marrow, causing severe anemia with low reticulocyte response. |
Infectious & TORCH Causes
| Question | Answer |
|---|---|
| 242. What is the mechanism of hyperbilirubinemia in Infectious Hepatitis / TORCH infections? | Direct viral/microbial intracellular injury to hepatocytes and cholangiocytes impairs both conjugation and canalicular excretion, causing mixed/conjugated hyperbilirubinemia. |
| 243. What physical skin lesion is pathognomonic for Congenital Cytomegalovirus (CMV) or Rubella? | Blueberry Muffin" rash (dermal extramedullary hematopoiesis presenting as dark blue-purpuric macules/papules). |
| 244. What skull radiograph / CT finding differentiates Congenital CMV from Congenital Toxoplasmosis? | Congenital CMV: Periventricular intracranial calcifications. Congenital Toxoplasmosis: Diffuse / Intraparenchymal scattered calcifications. |
| 245. What is the characteristic triad of Congenital Rubella Syndrome? | 1. Sensorineural Hearing Loss; 2. Cataracts / Microphthalmia; 3. Congenital Heart Disease (Patent Ductus Arteriosus / PDA, Pulmonary Artery Stenosis). |
| 246. What clinical triad characterizes Congenital Toxoplasmosis? | 1. Chorioretinitis; 2. Hydrocephalus; 3. Intracranial Calcifications. |
| 247. What radiological long bone finding is classic for Congenital Syphilis? | Wimberger Sign (localized bilateral symmetrical erosion of the medial proximal tibial metaphysis) and periostitis. |
| 248. What nasal presentation in a neonate suggests Congenital Syphilis? | Snuffles (persistent mucopurulent or bloody nasal discharge rich in spirochetes). |
| 249. How is Congenital Syphilis treated in a neonate? | Aqueous Crystalline Penicillin G: 50,000 units/kg/dose IV 12-hourly for first 7 days of life, then 8-hourly for total 10 days. |
| 250. What is the management of a neonate born to an HBsAg-positive mother? | Administer Hepatitis B Vaccine (0.5 mL IM) AND Hepatitis B Immunoglobulin (HBIG 0.5 mL IM) at separate anatomical sites within 12 hours of birth. |
Sepsis & Cholestasis Biochemistry
| Question | Answer |
|---|---|
| 251. What is the definition of Late-Onset Neonatal Sepsis presenting with jaundice? | Sepsis occurring ≥ 72 hours of life, commonly caused by Gram-negative bacilli (Klebsiella, E. coli, Pseudomonas) or Staphylococcus epidermidis, presenting with cholestasis, lethargy, temperature instability, and feeding intolerance. |
| 252. What mechanism causes cholestatic jaundice in Gram-negative bacterial sepsis (E. coli / Klebsiella)? | Circulating bacterial Endotoxins (LPS) and inflammatory cytokines (TNF-α, IL-6) downregulate hepatocyte canalicular bile transporters (BSEP, MRP2), inducing functional endotoxin-induced cholestasis. |
| 253. What is the significance of elevated Alkaline Phosphatase (ALP) and Gamma-Glutamyl Transferase (GGT) in neonatal jaundice? | Elevated ALP and GGT indicate biliary epithelial injury, ductal obstruction, or cholestasis. (Note: Serum ALP is also elevated in bone growth/rickets). |
| 254. What GGT level is typically seen in Biliary Atresia vs PFIC Type 1/2? | Biliary Atresia: Markedly High GGT (>300–500 IU/L). PFIC 1 and 2: Normal or Low GGT despite severe cholestasis. |
| 255. What ultrasound finding rules out extrahepatic biliary atresia? | Demonstration of a normal, contractile gallbladder (>1.5 cm) that contracts post-prandially and visualization of a patent common bile duct. |
| 256. What is the Gallbladder Ghost Triad on ultrasound in Biliary Atresia? | 1. Gallbladder length <1.9 cm; 2. Irregular or mucosal wall outline; 3. Lack of gallbladder contraction post-feed. |
Dietary & Medical Management of Cholestasis
| Question | Answer |
|---|---|
| 259. What dietary modification is mandatory in Galactosemia? | Immediate and permanent elimination of lactose/galactose from diet → Switch to Soy-based formula or Elemental lactose-free formula. (Breastfeeding is strictly contraindicated). |
| 260. What dietary modification is required in Hereditary Tyrosinemia Type 1? | Low-protein diet restricted in Phenylalanine and Tyrosine, combined with Nitisinone (NTBC) therapy. |
| 261. What enzyme inhibitor is Nitisinone (NTBC) in Tyrosinemia Type 1? | Inhibits 4-Hydroxyphenylpyruvate Dioxygenase (HPPD), preventing accumulation of toxic fumarylacetoacetate and succinylacetone. |
| 262. What vitamin deficiencies must be monitored and supplemented in chronic Neonatal Cholestasis? | Fat-soluble vitamins: A, D, E, and K (due to impaired micellar solubilization and fat malabsorption). |
| 263. What formulation of Vitamin E must be used in Cholestasis? | Tocopheryl Polyethylene Glycol Succinate (TPGS), a water-soluble form absorbed without bile salts. |
| 264. What dose of Vitamin K is given for coagulopathy in Cholestasis? | Parenteral / Oral Vitamin K1: 2 to 5 mg daily/biweekly. |
| 265. What type of dietary fat is recommended for infants with cholestasis and why? | Medium-Chain Triglyceride (MCT) oil; MCTs are absorbed directly into the portal circulation without requiring bile salt micellar solubilization. |
| 266. What drug is used to manage severe Pruritus in chronic cholestasis? | Rifampicin (10–15 mg/kg/day) (induces CYP enzymes/transporters), Ursodeoxycholic acid (UDCA), or Cholestyramine. |
| 267. How does Cholestyramine work? | An anion-exchange resin that binds bile acids in the intestinal lumen, preventing reabsorption and increasing fecal bile acid excretion. (Must be given 2 hours apart from other drugs). |
Biliary Atresia & Liver Transplantation
| Question | Answer |
|---|---|
| 268. What is Caroli Disease? | Congenital malformation characterized by non-obstructive segmental saccular dilatation of intrahepatic bile ducts (Classified as Todani Type V choledochal cyst). |
| 269. What syndrome combines Caroli Disease with Congenital Hepatic Fibrosis? | Caroli Syndrome (associated with Autosomal Recessive Polycystic Kidney Disease / ARPKD). |
| 270. What gene mutation causes Cystic Fibrosis presenting with neonatal cholestasis? | Mutation in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene (classically Δ F508), producing thick, inspissated biliary secretions that obstruct bile ductules. |
| 271. What is the primary cause of death in untreated Biliary Atresia? | Progressive secondary Biliary Cirrhosis, portal hypertension, esophageal variceal hemorrhage, hypersplenism, hepatic failure, and death by 1-2 years of age. |
| 272. What post-operative complication frequently causes failure of Kasai Portoenterostomy? | Recurrent ascending Cholangitis (treated with prophylactic antibiotics and pulse steroids). |
| 273. What percentage of infants undergoing successful Kasai surgery still ultimately require Liver Transplantation during childhood? | Approximately 70 to 80% eventually require liver transplantation before adulthood due to progressive chronic liver disease. |
| 274. What is the primary indication for pediatric Liver Transplantation in the neonatal/infantile age group? | Biliary Atresia (accounts for >50% of all pediatric liver transplants). |
Liver Examination & Dubin-Johnson / Rotor
| Question | Answer |
|---|---|
| 275. Describe the Palpation of Liver in a neonate with suspected liver disease. | Palpate smooth/nodular edge, liver span, firm/hard consistency, and distance below right costal margin in mid-clavicular line. (Normal term liver span is 4.5–6.0 cm; soft edge palpable up to 2 cm). |
| 276. What does a hard, nodular liver indicate in a 2-month-old infant? | Biliary Cirrhosis, Primary Liver Tumor (Hepatoblastoma, Infantile Hemangioendothelioma), or Storage Disease. |
| 277. What physical finding indicates Portal Hypertension secondary to biliary cirrhosis? | Splenomegaly, caput medusae / prominent abdominal wall veins, ascites, and gastrointestinal bleeding. |
| 278. What is Dubin-Johnson Syndrome? | Autosomal recessive conjugated hyperbilirubinemia caused by mutation in MRP2 (ABCC2) canalicular multidrug resistance protein, impairing direct bilirubin secretion. Liver appears black histologically due to lysosomal pigment. |
| 279. What is Rotor Syndrome? | Autosomal recessive conjugated hyperbilirubinemia caused by mutation in OATP1B1 and OATP1B3 hepatic uptake transporters. Liver histology is normal (no pigment). |
| 280. Differentiate Dubin-Johnson from Rotor Syndrome using Urinary Coproporphyrin excretion. | Dubin-Johnson: Total urinary coproporphyrin is normal, but Coproporphyrin I constitutes >80% of total. Rotor Syndrome: Total urinary coproporphyrin is markedly elevated (2–5times normal). |
Kramer Zones & Blood-Brain Barrier
| Question | Answer |
|---|---|
| 281. What is Kramer's Zone 5 boundaries, and what is its clinical significance? | Involves the palms and soles; indicates severe hyperbilirubinemia (TSB > 15–18 mg/dL), mandating urgent stat laboratory TSB testing. |
| 282. Why does hyperbilirubinemia progress in a Cephalocaudal (head-to-toe) direction? | Subcutaneous capillary blood flow, tissue lipophilic binding differences, and vascular processing gradients cause bilirubin deposition to manifest first in the face, extending downward to extremities. |
| 283. Why does resolution of jaundice occur in a Caudal-to-Cephalic (toe-to-head) direction? | Bilirubin is cleared first from peripheral vascular beds in lower limbs, clearing upward towards trunk and face last. |
| 284. At what age does the Blood-Brain Barrier mature in a full-term neonate? | Functional BBB tight junction maturity is established gradually over the first 7 to 10 days of life. |
| 285. Why are Late Preterm infants (34–36^{+6 weeks) at higher risk for Kernicterus than Full Term infants? | 1. Immaturity of hepatic UGT1A1 enzyme; 2. Lower serum albumin concentration; 3. Reduced albumin-binding affinity; 4. Immature blood-brain barrier integrity; 5. Higher rates of feeding difficulty/dehydration. |
| 286. What is Bilirubin Encephalopathy Risk Index? | The ratio of Total Serum Bilirubin (mg/dL) to Serum Albumin (g/dL); values >0.8–1.0 indicate high free bilirubin and elevated neurotoxicity risk. |
| 287. What is the effect of Maternal Diabetes on neonatal bilirubin levels? | Fetal hyperinsulinemia increases erythropoietin → causes fetal polycythemia → increases RBC mass breakdown post-birth. Also, macrosomia increases extravasated birth trauma hemorrhage. |
| 288. How does Intestinal Obstruction (Duodenal Atresia, Hirschsprung disease) cause severe early hyperbilirubinemia? | Intestinal stasis delays meconium passage; unabsorbed intestinal meconium contains ≈ 100–200 mg of unconjugated bilirubin which is reabsorbed via enterohepatic circulation. |
| 289. What volume of meconium is passed in the first 24 hours by a normal term infant? | ≈ 60 to 100 grams of meconium containing significant quantities of unconjugated bilirubin. |
| 290. Why does Delayed Cord Clamping increase the risk of mild hyperbilirubinemia? | Placental transfusion increases neonatal blood volume and RBC mass by 20–30%, generating a larger daily heme breakdown load. (Benefits outweigh risks). |
Risk Stratification & Hemolysis
| Question | Answer |
|---|---|
| 291. What is the AAP 2022 definition of Hyperbilirubinemia Neurotoxicity Risk Factors? | Hyperbilirubinemia risk factors include: Gestational age <38 weeks, albumin <3.0 g/dL, isoimmune hemolytic disease, G6PD deficiency, sepsis, or significant clinical instability in preceding 24 hours. |
| 292. What is Low-Birth-Weight / Preterm Phototherapy Threshold general rule of thumb? | Phototherapy is typically initiated at a TSB numerical level equal to 0.5 to 1% of birth weight in grams (e.g., 1000 g baby → start phototherapy at 5 to 7 mg/dL; 1500 g baby → start at 7 to 9 mg/dL). |
| 293. What is the Exchange Transfusion threshold rule of thumb for preterm infants? | Exchange transfusion is initiated at a TSB numerical level equal to 1% of birth weight in grams (e.g., 1000 g baby → exchange at 10 mg/dL; 1500 g baby → exchange at 15 mg/dL). |
| 294. What is Bilirubin-Induced Sialadenitis? | Transient swelling of parotid/submandibular salivary glands secondary to ductal obstruction caused by severe hyperbilirubinemia or phototherapy. |
| 295. What is the effect of Hypothermia on bilirubin neurotoxicity? | Hypothermia induces free fatty acid release via cold-induced lipolysis; free fatty acids displace bilirubin from albumin, increasing free bilirubin levels. |
| 296. What is the effect of Infection / Sepsis on the Blood-Brain Barrier? | Systemic inflammatory cytokines (IL-1β, TNF-α) disrupt endothelial tight junctions, facilitating brain entry of albumin-bound and free bilirubin. |
| 297. What is End-Tidal Carbon Monoxide corrected (ETCOc) measurement? | Breath test measuring exhaled CO in ppm; values >2.0 ppm indicate active hemolysis. |
| 298. Why is COoximetry useful in hemolytic disease evaluation? | Measures carboxyhemoglobin (COHb) in blood, providing a quantitative index of active in vivo heme degradation. |
| 299. What is the Coombs Negative Hemolytic Anemia differential panel? | 1. G6PD Deficiency; 2. Pyruvate Kinase Deficiency; 3. Hereditary Spherocytosis / Elliptocytosis; 4. Microangiopathic Hemolysis (DIC, Sepsis); 5. Vitamin E Deficiency (in preterms). |
| 300. What is the effect of Maternal Smoking on neonatal jaundice risk? | Maternal smoking is associated with a decreased incidence of neonatal hyperbilirubinemia (induction of maternal/fetal hepatic UGT1A1 enzyme activity by polycyclic aromatic hydrocarbons). |
Phototherapy — Advanced Topics
| Question | Answer |
|---|---|
| 301. What is the primary route of excretion for Lumirubin? | Excreted directly into Bile and Urine without requiring glucuronide conjugation or hepatic transport processing. |
| 302. What percentage of total serum bilirubin reduction under phototherapy is contributed by Lumirubin formation? | Lumirubin structural isomerization accounts for >85% of total bilirubin clearance during phototherapy. |
| 303. Why is green light (500 nm) theoretically capable of penetrating deeper into skin than blue light (460 nm)? | Longer wavelengths penetrate subcutaneous tissue deeper; however, blue light (460–490 nm) matches bilirubin’s peak absorption spectrum (458 nm) far better, making blue light clinically superior. |
| 304. What distance modification increases irradiance when using fluorescent lights? | Moving the lamp closer from 45 cm to 15 cm increases light intensity by 300% (inverse square law). |
| 305. Why can Halogen lamps NOT be placed closer than 40 cm to the neonate? | Halogen lights emit significant thermal infrared heat, causing high risk of cutaneous burns and hyperthermia. |
| 306. What is Fiberoptic Phototherapy? | Light from a quartz-halogen or LED bulb is transmitted through a fiberoptic cable into a flexible woven pad wrapped directly around the infant's trunk. |
| 307. What is the main advantage of Fiberoptic Phototherapy blankets? | Allows mother to hold, feed, and bond with the infant during continuous phototherapy without eye patches. |
| 308. What is Aggressive / High-dose Phototherapy risk in extremely low birth weight (ELBW <750 g) infants? | High irradiance in tiny ELBW infants with thin skin has been associated with increased mortality due to photo-oxidative cell membrane damage; low-power phototherapy is recommended in ELBW. |
| 309. What laboratory artifact occurs when blood drawn under phototherapy is exposed to ambient light? | Bilirubin in un-covered glass tubes photo-degrades rapidly, causing false low TSB results (tubes must be wrapped in foil or amber-colored). |
| 310. How is Unbound / Free Bilirubin (Bf) measured directly in specialized laboratories? | Measured using the Peroxidase Assay Method (horseradish peroxidase oxidizes unbound bilirubin, leaving albumin-bound bilirubin untouched). |
| 311. What is the Bilicheck or JM-105? | Commercial handheld Transcutaneous Bilirubinometer devices utilizing optical spectrophotometry to measure skin dermal bilirubin. |
| 312. At what anatomical sites should Transcutaneous Bilirubin (TcB) be measured? | Medial Sternum or Forehead. (Sternum is preferred as it is less exposed to ambient room light). |
| 313. What is the correlation coefficient (r) between TcB and TSB in un-treated term infants? | Strong positive correlation (r = 0.88 to 0.93) for TSB levels <15 mg/dL. |
| 314. If a TcB reading is 12 mg/dL and the phototherapy threshold is 14 mg/dL, what is the action? | TcB is within 3 mg/dL of threshold → Obtain confirmation Total Serum Bilirubin (TSB) blood test. |
| 315. Can TcB be used to screen for hyperbilirubinemia in preterms <35 weeks? | TcB is validated primarily for ≥ 35 weeks gestation. In preterms <35 weeks, TcB can be used for screening but has wider confidence intervals; confirm with TSB. |
| 316. What is the role of Home Phototherapy? | Safe for low-risk term infants (>48 hours old, TSB 2–3 mg/dL below exchange line, no hemolysis, good feeding, reliable parents with daily TSB monitoring). |
| 317. When should a repeat TSB be checked after stopping phototherapy in a non-hemolytic infant? | Rebound TSB check is NOT routinely necessary in low-risk non-hemolytic infants unless discharge occurs <24 hours post-stopping. |
| 318. What is the ACOG / AAP recommendation for management of Rh-negative mothers undergoing external cephalic version, chorionic villus sampling, or miscarriage? | Administer 300μg Anti-D Immunoglobulin within 72 hours of event. |
Minor Blood Groups & G6PD
| Question | Answer |
|---|---|
| 319. What is Isoimmune Anti-E or Anti-c Hemolytic Disease? | Hemolytic disease caused by maternal IgG against minor Rh antigens E or c, capable of causing severe anemia/jaundice requiring exchange transfusion. |
| 320. What is Kell Isoimmunization pathophysiology? | Anti-Kell IgG targets Kell antigens expressed on early erythroid progenitor cells (CFU-E) in fetal bone marrow, suppressing fetal RBC production and causing severe fetal anemia with minimal hyperbilirubinemia. |
| 321. How does G6PD Deficiency cause non-hemolytic hyperbilirubinemia? | Concurrent promoter polymorphism in the UGT1A1 gene (Gilbert mutation) in G6PD-deficient infants impairs hepatic bilirubin conjugation independently of active hemolysis. |
| 322. What geographic populations have high prevalence of G6PD Deficiency? | Mediterranean, Middle East, Sub-Saharan Africa, South-East Asia, and specific Indian communities (Parsis, Bhanushalis, tribal populations). |
| 323. What food ingestion by a nursing mother can precipitate acute hemolysis in a G6PD-deficient infant? | Fava beans (Favism) (contain vicine and convicine which generate oxidative stress). |
| 324. What chemical compound used in mothballs or clothes storage triggers severe G6PD hemolysis in newborns? | Naphthalene (absorbed through skin or inhalation from stored clothes/swaddles). |
| 325. What traditional skin application used in South Asia / Middle East causes severe G6PD hemolysis? | Henna (Lawsonia inermis) applied to newborn skin or umbilical stump. |
| 326. What is Infantile Pyknocytosis? | A transient infantile hemolytic anemia characterized by prominent Pyknocytes (distorted, dense, spiculated RBCs) on peripheral blood smear, presenting with severe jaundice in the 1st week and resolving spontaneously by 4-6 months. |
Metabolic & Endocrine Causes
| Question | Answer |
|---|---|
| 327. What is the primary energy substrate required by UGT1A1 enzyme for glucuronidation? | UDP-Glucuronic Acid (derived from glucose metabolism via UDP-glucose dehydrogenase). |
| 328. Why does Starvation / Inadequate Caloric Intake worsen unconjugated hyperbilirubinemia? | Depletes hepatic glycogen and UDP-glucuronic acid substrate levels, impairing UGT1A1 conjugation efficiency, and increases intestinal transit time, accelerating enterohepatic reabsorption. |
| 329. What is the effect of Maternal Hypothyroidism on neonatal jaundice? | Maternal hypothyroidism increases risk of congenital hypothyroidism in the infant, presenting with prolonged physiological jaundice. |
| 330. What is Lucey-Driscoll Syndrome inhibitory factor? | Unidentified progestational steroid present in maternal serum during 3rd trimester that potently inhibits fetal UGT1A1 activity. |
| 331. How does Congenital Hypertrophic Pyloric Stenosis cause jaundice? | Dehydration, starvation (low UDP-glucuronic acid), and gastric outlet obstruction increase intestinal transit time and enterohepatic circulation. Jaundice resolves rapidly after Ramstedt Pyloromyotomy. |
| 332. What is Transient Neonatal Cholestasis? | Mild, self-limiting cholestasis in sick preterms or asphyxiated infants secondary to transient ischemia, delayed feeding, or sepsis, resolving completely with supportive care. |
| 333. What metabolic disorder presents with cholestasis, hepatomegaly, and cataracts? | Galactosemia (Galactose-1-Phosphate Uridylyltransferase / GALT deficiency). |
| 334. What metabolic disorder presents with cholestasis, seizures, dysmorphic facies, and renal cysts? | Zellweger Syndrome (Peroxisomal biogenesis disorder). |
| 335. What metabolic disease presents with cholestasis, hypoglycemia, and microphallus in a male infant? | Congenital Hypopituitarism / Panhypopituitarism (growth hormone and ACTH deficiency impairing bile acid synthesis and flow). |
Biliary Atresia Surgery & PFIC / Alagille
| Question | Answer |
|---|---|
| 336. What is the Kasai Portoenterostomy Success Rate when performed at <60 days vs >90 days of life? | <60 days: 70 to 80% achieve bile drainage. >90 days: <20 to 25% achieve bile drainage (due to irreversible cirrhosis). |
| 337. What adjuvant medical treatment is given post-Kasai surgery to promote bile flow and prevent cholangitis? | 1. High-dose Corticosteroids (Prednisolone) for 4-6 weeks; 2. Prophylactic Antibiotics (Trimethoprim-Sulfamethoxazole / Neomycin); 3. Ursodeoxycholic Acid (UDCA). |
| 338. What is Paucity of Intrahepatic Bile Ducts (PIBD)? | Histological reduction of bile duct-to-portal tract ratio to <0.4 (normal is 0.9–1.8). Seen in Alagille syndrome, metabolic diseases, or idiopathic PIBD. |
| 339. What is the characteristic facies of Alagille Syndrome? | Triangular face, broad forehead, deep-set widely spaced eyes (hypertelorism), long straight nose with bulbous tip, and pointed chin. |
| 340. What cardiovascular anomaly is most commonly associated with Alagille Syndrome? | Peripheral Pulmonary Artery Stenosis (or Tetralogy of Fallot). |
| 341. What vertebral anomaly is pathognomonic for Alagille Syndrome on chest/spine X-ray? | Butterfly Vertebrae (sagittal cleft in vertebral bodies due to failure of anterior fusion). |
| 342. What is Progressive Familial Intrahepatic Cholestasis Type 3 (PFIC-3) gene defect? | Mutation in MDR3 (ABCB4) gene encoding the canalicular phospholipid flippase, preventing phosphatidylcholine secretion into bile → unbuffered bile salts injure cholangiocytes → high GGT cholestasis. |
| 343. What is the surgical procedure Biliary Diversion (Partial External Biliary Diversion / PEBD)? | Surgical creation of a stoma diverting 30–50% of bile outside the body, disrupting enterohepatic circulation to relieve severe pruritus in PFIC 1 and 2. |
| 344. What is the MRCP (Magnetic Resonance Cholangiopancreatography) role in neonatal cholestasis? | Non-invasively visualizes extrahepatic biliary tree; however, small infant bile duct size limits sensitivity compared to intraoperative cholangiography. |
| 345. What is the Gold Standard diagnostic test to definitively confirm or rule out Biliary Atresia? | Intraoperative Cholangiography (IOC) during exploratory laparotomy / laparoscopy. |
| 346. Describe the Intraoperative Cholangiography findings in Biliary Atresia. | Inability to cannulate micro-gallbladder, or injection of radiopaque contrast shows failure of contrast to pass into intrahepatic bile ducts or down into duodenum. |
| 347. What is Inspiratory / Expiratory Chest Radiograph finding in neonatal cholestasis with suspected alpha-1 antitrypsin deficiency? | May show hyperinflation or early basilar emphysematous changes (though emphysema typically develops in early adulthood). |
| 348. What is the recommended calorie intake for an infant with chronic cholestatic liver disease? | 130 to 150% of RDA (140–160 kcal/kg/day) due to fat malabsorption and hypermetabolic state. |
| 349. What percentage of total dietary calories should be supplied as MCT oil in cholestatic infants? | 30 to 50% of total dietary fat intake as MCT oil. |
Public Health Goals
| Question | Answer |
|---|---|
| 350. Summarize the primary goals of the National Global Goal for Neonatal Jaundice Management. | Elimination of avoidable Bilirubin Encephalopathy / Kernicterus by 2030 through universal post-natal pre-discharge bilirubin screening, hour-specific risk stratification, maternal Rh prophylaxis, standardized phototherapy guidelines, and early Kasai referral for cholestasis. |